Castle Biosciences Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 1,048

Employees

  • Stock Symbol
  • CSTL

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $32.91
  • (As of Friday Closing)

Castle Biosciences General Information

Description

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1500 West Parkwood Avenue
  • Suite 400
  • Friendswood, TX 77546
  • United States
Primary Industry
Laboratory Services (Healthcare)
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1500 West Parkwood Avenue
  • Suite 400
  • Friendswood, TX 77546
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Castle Biosciences Stock Performance

As of 20-Nov-2026, Castle Biosciences’s stock price is $32.91. Its current market cap is $1.01B with 30.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$32.91 $33.41 $17.72 - $44.28 $1.01B 30.8M 385K -$0.77

Castle Biosciences Financials Summary

As of 30-Sep-2026, Castle Biosciences has a trailing 12-month revenue of $377M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 855,269 885,036 493,350 365,503
Revenue 377,126 344,229 332,069 219,788
EBITDA (16,425) (429) 25,222 (55,647)
Net Income (23,014) (24,158) 18,245 (57,466)
Total Assets 579,408 578,556 531,235 453,340
Total Debt 36,574 36,913 26,344 15,335
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Castle Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Castle Biosciences‘s full profile, request access.

Request a free trial

Castle Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Castle Biosciences‘s full profile, request access.

Request a free trial

Castle Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treat
Laboratory Services (Healthcare)
Friendswood, TX
1,048 As of 2026

Salt Lake City, UT
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Castle Biosciences Competitors (28)

One of Castle Biosciences’s 28 competitors is Myriad Genetics, a Corporation company based in Salt Lake City, UT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Myriad Genetics Corporation Salt Lake City, UT
Veracyte Formerly VC-backed South San Francisco, CA
Biocept Formerly VC-backed San Diego, CA
Decipher Urologic Cancers Formerly VC-backed San Diego, CA
Cardiff Oncology Formerly Angel backed San Diego, CA
You’re viewing 5 of 28 competitors. Get the full list »

Castle Biosciences Patents

Castle Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026183498-A1 Diagnosing and treatment uveal melanoma Pending 28-Feb-2025
WO-2026036140-A1 Method and kit for isolating and sequencing nucleic acid from skin samples Pending 09-Aug-2024
EP-4676593-A1 Diagnosing and treating atopic dermatitis, psoriasis, and/or mycosis fungoides Pending 10-Mar-2023
WO-2024191957-A1 Diagnosing and treating atopic dermatitis, psoriasis, and/or mycosis fungoides Inactive 10-Mar-2023
US-20220285032-A1 Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores Inactive 08-Mar-2021 G16H50/30
To view Castle Biosciences’s complete patent history, request access »

Castle Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Castle Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Castle Biosciences‘s full profile, request access.

Request a free trial

Castle Biosciences Investments & Acquisitions (5)

Castle Biosciences’s most recent deal was a PIPE with SciBase for . The deal was made on 17-Jun-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
SciBase 17-Jun-2025 PIPE Diagnostic Equipment
Previse (Biotechnology) 01-May-2025 Merger/Acquisition Diagnostic Equipment
AltheaDx 26-Apr-2022 Merger/Acquisition Practice Management (Healthcare)
Cernostics 03-Dec-2021 Merger/Acquisition Decision/Risk Analysis
Myriad myPath Melanoma 28-May-2021 Merger/Acquisition Diagnostic Equipment
To view Castle Biosciences’s complete investments and acquisitions history, request access »

Castle Biosciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

21.9 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Services

Subindustry

of 97

Rank

Percentile

To view Castle Biosciences’s complete esg history, request access »

Castle Biosciences FAQs

  • When was Castle Biosciences founded?

    Castle Biosciences was founded in 2008.

  • Where is Castle Biosciences headquartered?

    Castle Biosciences is headquartered in Friendswood, TX.

  • What is the size of Castle Biosciences?

    Castle Biosciences has 1,048 total employees.

  • What industry is Castle Biosciences in?

    Castle Biosciences’s primary industry is Laboratory Services (Healthcare).

  • Is Castle Biosciences a private or public company?

    Castle Biosciences is a Public company.

  • What is Castle Biosciences’s stock symbol?

    The ticker symbol for Castle Biosciences is CSTL.

  • What is the current stock price of Castle Biosciences?

    As of 20-Nov-2026 the stock price of Castle Biosciences is $32.91.

  • What is the current market cap of Castle Biosciences?

    The current market capitalization of Castle Biosciences is $1.01B.

  • What is Castle Biosciences’s current revenue?

    The trailing twelve month revenue for Castle Biosciences is $377M.

  • Who are Castle Biosciences’s competitors?

    Myriad Genetics, Veracyte, Biocept, Decipher Urologic Cancers, and Cardiff Oncology are some of the 28 competitors of Castle Biosciences.

  • What is Castle Biosciences’s annual earnings per share (EPS)?

    Castle Biosciences’s EPS for 12 months was -$0.77.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process